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Abstract 
Background: Bronchial asthma is a heterogeneous disease characterized by three cardinal features: chronic inflam-
mation, variable airflow obstruction, and airway hyperresponsiveness. Asthma has traditionally been defined using 
nonspecific clinical and physiologic variables that encompass multiple phenotypes and are treated with nonspecific 
anti-inflammatory therapies. Based on the modulation of airway remodeling after 12 months of anti-immunoglobulin 
E (IgE) treatment, we identified two phenotypes (omalizumab responder, OR; and non-omalizumab responder, NOR) 
and performed morphometric analysis of bronchial biopsy specimens. We also found that these two phenotypes 
were correlated with the presence/absence of galectin-3 (Gal-3) at baseline (i.e., before treatment). The aims of the 
present study were to investigate the histological and molecular effects of long-term treatment (36 months) with 
anti-IgE and to analyze the behavior of OR and NOR patients.
Methods: All patients were treated with the monoclonal antibody anti-IgE omalizumab for 36 months. The bronchial 
biopsy specimens were evaluated using morphometric, eosinophilic, and proteomic analysis (MudPIT). New data 
were compared with previous data, and unsupervised cluster analysis of protein profiles was performed.
Results: After 36 months of treatment with omalizumab, reduction of reticular basement membrane (RBM) thickness 
was confirmed in OR patients (Gal-3-positive at baseline); similarly, the protein profiles (over 500 proteins identified) 
revealed that, in the OR group, levels of proteins specifically related to fibrosis and inflammation (e.g., smooth muscle 
and extracellular matrix proteins (including periostin), Gal-3, and keratins decreased by between 5- and 50-fold. Eosin-
ophil levels were consistent with molecular data and decreased by about tenfold less in ORs and increased by twofold 
to tenfold more in NORs. This tendency was confirmed (p < 0.05) based on both fold change and DAVE algorithms, 
thus indicating a clear response to anti-IgE treatment in Gal-3-positive patients.
Conclusions: Our results showed that omalizumab can be considered a disease-modifying treatment in OR. The pro-
teomic signatures confirmed the presence of Gal-3 at baseline to be a biomarker of long-term reduction in bronchial 
RBM thickness, eosinophilic inflammation, and muscular and fibrotic components in omalizumab-treated patients 
with severe asthma. Our findings suggest a possible relationship between Gal-3 positivity and improved pulmonary 
function.
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Background
Bronchial asthma is a heterogeneous disease character-
ized by three cardinal features: chronic inflammation, 
variable airflow obstruction, and airway hyperrespon-
siveness [1]. The heterogeneity of asthma extends beyond 
clinical symptoms, response to therapy, age at onset, 
duration of disease process, extent of bronchial narrow-
ing, sensitivity to triggering agents, airway inflammatory 
pattern, and the immune response. Accordingly, clas-
sifying asthma into several smaller, more homogeneous 
subgroups, the so-called phenotypes, makes it easier to 
define the underlying mechanisms of the disease, admin-
ister more effective mechanism-based therapy, and 
improve prediction of disease course.
Technological advances during the last decade have 
facilitated clinical and molecular research, thus making it 
possible to combine phenotyping approaches to optimize 
asthma management and personalized medicine [2].
The US Severe Asthma Research Program (SARP) 
recently analyzed an extensive dataset of patients with 
severe and nonsevere asthma in order to identify and 
describe robust subgroups of asthma patients with spe-
cific features [3] that could guide personalized therapy, 
although this approach has not yet been verified. Using 
a variety of statistical analyses, the authors interrogated 
the dataset to identify the characteristics that most accu-
rately distinguish between subgroups within the study 
population. This approach is known as clustering [1].
Asthma has traditionally been defined using nonspe-
cific clinical and physiological variables that encompass 
multiple phenotypes and has been treated using nonspe-
cific anti-inflammatory therapies. Recent molecular and 
genetic studies have identified clinical and inflammatory 
phenotypes associated with specific biomarkers.
Biomarkers for inflammation driven by type-2 helper T 
lymphocytes (Th2), including elevated fractional exhaled 
nitric oxide (FeNO) levels, blood/sputum eosinophil 
counts, and serum periostin levels, have helped to iden-
tify a Th2-high molecular phenotype of asthma. Treat-
ment of Th2-high asthmatic patients with biologic agents 
targeting immunoglobulin E (IgE) and the canonical 
Th2-related cytokines interleukin (IL) 4, IL-5, and IL-13 
is proving to be efficacious [4]. However, we do not yet 
know the biomarkers able to identify a Th2-low asthma 
phenotype and potentially guide therapy. Although tar-
geted biologic agents are generally efficacious in treat-
ing various phenotypes of asthma and allergic disease, 
some patients respond better to one biologic agent than 
another or not at all. The reasons for these differential 
responses are still unknown [5].
We performed morphometric analysis on bronchial 
biopsy specimens before and after anti-IgE treatment 
to investigate modulation (or not) of airway remodeling 
after 12 months of treatment with omalizumab. We iden-
tified two phenotypes of severe asthma: the omalizumab 
responder phenotype (OR) and the non-omalizumab 
responder phenotype (NOR) [6]. Proteomic analysis 
of the specimens showed that these patient subgroups 
were characterized by different levels of galectin-3 (Gal-
3) in bronchial tissue at baseline and after 12 months of 
treatment with omalizumab [7]. In the present study, 
we extended our morphometric, eosinophilic, and pro-
teomic analyses by investigating bronchial biopsy speci-
mens collected from the same patients after 36  months 
of treatment with omalizumab and compared molecular 
data with data on bronchial reticular basement mem-
brane (RBM) thickness and bronchial eosinophilic and 
neutrophilic infiltration.
The aims of the present study were to evaluate prot-
eomic signatures and modifications in RBM thickness 
with respect to long-term anti-IgE treatment and to 
investigate the behaviour of OR and NOR.
Methods
Patients
Eight patients were treated with the monoclonal anti-
body anti-IgE omalizumab for 36  months. The patients’ 
clinical features (Table  1) were described in a previous 
paper, where we showed that the original RBM thickness 
and eosinophil infiltration were reduced in a substantial 
proportion of severe asthmatics after 1 year of treatment 
with omalizumab, thus emphasizing the possible role 
of this agent in airway remodelling in severe persistent 
allergic asthma [6].
Keywords: Anti-IgE, Omalizumab, Severe asthma, Galectin-3, Biomarker, Airway remodeling, Bronchial biopsy, 
Proteomics, Eosinophils
Table 1 Patient characteristics
Data are expressed as mean ± SEM
Patients (n) 8
Age (years) 47.0 ± 9.7
Sex ratio (M/F) 5/3
Smokers/nonsmokers 1/7
Body mass index 23.8 ± 3.1
Total plasma IgE (kU/L) 309.4 ± 218.2
Forced expiratory volume in the first second 52% pred ± 14%
Asthma control test score 11.3 ± 2.8
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The study was approved by the Ethics Committee of 
Orlandi General Hospital of Bussolengo, Verona, Italy.
Bronchial biopsy: collection and processing
As previously reported before treatment and at 
12  months [6], each patient underwent bronchoscopy 
36  months after starting anti-IgE treatment. Bronchial 
biopsy specimens were obtained using a flexible bron-
choscope (Pentax FB19-TX, Langley, UK). Specimens 
were collected from the right middle lobe, fixed in forma-
lin for 10 h at 4 °C, and embedded in paraffin. The blocks 
were cut into 3-µm sections using a rotary microtome.
Morphometric analysis
The bronchial sections were mounted onto glass slides, 
dewaxed, rehydrated, and stained with hematoxylin-eosin 
(Hematoxylin and Eosin Stain, Carl Roth GmbH +  Co. 
KG, Germany).
The area of the RBM was measured using computer-
aided digital morphometry with a DFC 320 Leica color 
digital camera attached to a Leica Microsystems DMLA 
light microscope. Digital images of the biopsies were 
captured at high power using a 100× lens and analyzed 
using QWin software (Leica Microsystems). Bronchial 
RBM thickness was measured according to the recom-
mendations of the American Thoracic Society/Euro-
pean Respiratory Society using the orthogonal intercept 
method. A 100 × 100-μm grid was randomly overlaid on 
hematoxylin-eosin-stained sections. Orthogonal inter-
cepts were measured from the intersections of the grid 
with the RBM-epithelium junction to the RBM-subepi-
thelial area junction. At least 40 measures were obtained 
every 20  μm. Morphometric analysis was performed 
by two blinded operators. The arithmetic means of the 
intercept measures were calculated using the formula 
τ = π/4 × arithmetic mean of orthogonal intercepts [8].
Evaluation of the eosinophilic infiltrate
Bronchial biopsies collected 36  months after start-
ing treatment with omalizumab were considered suit-
able for examination if at least 1.0  mm of RBM length 
and 0.1  mm2 of subepithelial area were morphometri-
cally preserved. Eosinophils were quantified in the 
area extending 50 μm under the RBM and expressed as 
number of eosinophils/mm2 of subepithelium (mean of 
two samples per patient). The eosinophil count was per-
formed by two blinded operators [9].
Evaluation of the neutrophilic infiltrate
In order to obtain complete data on the bronchial inflam-
matory pattern, we evaluated neutrophilic infiltration 
before treatment and after 36 months. This variable was 
not investigated in our previous paper [6]. Biopsies were 
considered suitable for examination when there was at 
least 1.0 mm of RBM length and 0.1 mm2 of subepithe-
lial area. Neutrophils were quantified in the area extend-
ing 50  μm under the RBM and expressed as number of 
neutrophils/mm2 of subepithelium. The neutrophil count 
was performed by two blinded operators [9].
Proteomic analysis
The dewaxed tissues (3-µm section from each sample) 
were dried in a vacuum centrifuge and resuspended in 
0.1  M ammonium bicarbonate, pH 7.9. Proteins were 
extracted from tissue as previously described [7]. Briefly, 
tissue was homogenized in solution buffer (0.1 M ammo-
nium bicarbonate, pH 7.9) treated with RapiGest SF 
reagent (Waters Corporation, Milford, MA, USA) and 
incubated with stirring, first at 100  °C for 20  min and 
then at 80  °C for 2  h. Subsequently, the protein con-
centration was assayed using the SPNTM Protein Assay 
kit (G-Biosciences, Maryland Heights, MO, USA), and 
5 ± 0.5 µg of protein from each sample was digested with 
trypsin (Sequencing Grade Modified Trypsin, Promega, 
Madison, WI, USA) using a 1:50 (w/w) enzyme/substrate 
ratio at 37 °C overnight. The next morning, an additional 
aliquot of enzyme was added at an enzyme/substrate 
ratio of 1:100 (w/w), and digestion was continued for 4 h. 
Enzyme digestion was stopped by addition of trifluoro-
acetic acid to reach a pH of 2, and the digested samples 
were desalted and enriched using PepClean columns 
(Pierce Biotechnology, Rockford, IL, USA).
The resulting peptide mixtures were analyzed using 
multidimensional protein identification technology 
(MudPIT) [10] based on two-dimensional chromatog-
raphy coupled to tandem mass spectrometry (2DC-MS/
MS). Peptides were identified to correlate the experi-
mental tandem mass spectra with the theoretical peptide 
sequences obtained by the in silico digestion of a human 
protein database (approximately 230,000 entries) down-
loaded from the NCBI website (www.ncbi.nlm.nih.gov).
Statistical and clustering analyses
Mass spectra data were processed using Bioworks ver-
sion 3.3.1 based on the SEQUEST algorithm (Univer-
sity of Washington, licensed to Thermo Finnigan Corp., 
San José, CA, USA) and the following parameters: 
Xcorr scores greater than 1.5 for singly charged peptide 
ions and 2.0 and 2.5 for doubly and triply charged ions, 
respectively; peptide probability ≤0.001; and protein 
consensus score value ≥10. These filters guaranteed that 
the resulting proteins had a p value of ≤0.001. The false-
positive peptide ratio, which was calculated through the 
reverse database, was less than 3%.
The statistical analysis was performed using R soft-
ware. Biological and technical replicates were evaluated 
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by hierarchical clustering [11] using an in-house R script 
based on the XlsReadWrite, clue, and clValid libraries 
(http://cran.r-project.org). The Euclidean distance met-
ric was applied and an agglomerative coefficient was 
calculated.
We measured five parameters (eosinophils, smooth 
muscle proteins, periostin, keratins, and RBM) in eight 
patients (OR, n =  4; NOR, n =  4) and separated them 
according to time (T0, and T36) to evaluate significant 
differences between OR and NOR. For each group, sig-
nificant differences were also evaluated between baseline 
(T0) and T36.
As for eosinophils (cells/mm2), the t test (p  ≤  0.05) 
was used to evaluate the difference between the patient 
groups (OR and NOR) and treatment time (T0 and T36). 
The same comparisons were performed for periostin, 
Gal-3, smooth muscle proteins, and keratins. In this case, 
the average SEQUEST score values were evaluated using 
the Wilcoxon test because proteomic data are not nor-
mally distributed (Shapiro–Wilk test).
Variation in the proteins analyzed was also evaluated 
by calculating the fold change, as previously reported 
[12]; this was defined as the natural logarithm of the 
ratio T36/T0. In addition, the protein lists were analyzed 
and aligned using multidimensional algorithm protein 
map software (MAProMa), which provides quantitative 
indexes based on the SEQUEST score, such as DAVE and 
DCI [13]. DAVE is an index of the ratio between the two 
conditions compared and, therefore, indicates different 
amounts of each protein under the two different condi-
tions. When the protein is not present in the reference 
(baseline), DAVE is +2.0, whereas if the protein is not 
present in the sample (in our case after treatment, T36), 
DAVE is −2.0. Consequently, intermediate DAVE val-
ues indicate different amounts of protein under the two 
conditions compared. DAVE values >|0.4| indicate sig-
nificant variations. Finally, the t test was used to evalu-
ate significant differences in the average DAVE and fold 
change values.
Results
We evaluated the effect of long-term anti-IgE treatment 
(36  months) on RBM thickness, eosinophilic and neu-
trophilic infiltrates, and proteomic profiles by analyzing 
bronchial biopsy specimens from patients with severe 
asthma (Table 1).
Histological analysis
All bronchial biopsies were evaluated using morphomet-
ric analysis of RBM thickness.
Differences were observed in the behavior of the two 
groups (OR and NOR) between baseline and 36 months 
of anti-IgE treatment.
Analysis of bronchial tissue in the OR patients revealed 
a consistent reduction in RBM thickness; conversely, 
analysis of the NOR patients revealed an increase in RBM 
thickness despite treatment with omalizumab (Fig. 1).
As for subepithelial eosinophils, our data showed 
that the eosinophilic infiltrate doubled (7–15/mm2) in 
NOR patients after 36 months. Analysis of biopsy speci-
mens from the OR patients, on the other hand, revealed 
the presence of eosinophils to be about 10 times lower 
(55–5/mm2) (Fig.  2). The difference between OR and 
NOR was significant (p < 0.05; fold change = ln[T36/T0]) 
(Additional file 1).
Evaluation of the neutrophilic infiltrate revealed no dif-
ferences between the two groups. Moreover, the number 
of neutrophils in bronchial specimens at baseline, after 
both 12 months and 36 months was very low and negligi-
ble (data not shown).
Protein profile
MudPIT made it possible to identify 546 distinct proteins 
(see Additional file  2 for a complete list of the proteins 
identified for each sample). Using the MAProMa software, 
each protein list was automatically plotted onto a 2D map 
according to the theoretical molecular weight (MW) and 
isoelectric point (pI) of the proteins identified. A repre-
sentative example is reported in Additional file  3, which 
shows the 2D maps corresponding to all the proteins iden-
tified, thus confirming the possibility of characterizing 
proteins with extreme theoretical MW values (<10  kDa) 
and proteins with extreme pI values (<4 or >10).
In our previous study [6], the main differences at 
12  months affected the cytoskeleton, mainly smooth 
muscle and keratins, and ECM proteins. With respect 
to ECM proteins, analysis of the biopsy specimens at 
36 months revealed the same trend of proteomic signa-
ture for patients who were Gal-3-positive before treat-
ment (OR); in contrast, protein behavior was different 
in patients who were Gal-3-negative before treatment 
(NOR).
In the OR group, smooth muscle proteins (including 
myosins, tropomyosins, and actins) had decreased to very 
low levels at 36 months (from 265 to 8 [aggregate score]; 
average ln[T36/T0], about –4.0; DAVE, –1.89) in the OR 
group (Gal-3-positive biopsies). In the NOR group (Gal-
3-negative biopsies), protein levels increased from 5 to 74 
(average ln[T36/T0], around +2.5; DAVE, +1.75) (Fig. 3; 
Additional files 1, 4). The difference between the two 
groups was almost significant (p < 0.01).
As for keratins, the trend at 36  months of treatment 
was more consistent for OR (Gal-3 positive) (about six-
fold less, from 1800 to 300 as the average score; average 
ln[T36/T0], −2; DAVE −1.45) than NOR (both DAVE 
and average ln[T36/T0], low stringent). In this case the 
Page 5 of 10Riccio et al. Clin Transl Allergy  (2017) 7:6 
difference was not significant (p = 0.19; see Fig. 4; Addi-
tional files 1, 4).
ECM proteins, which were present almost exclusively at 
baseline in OR (Gal-3-positive) patients, also maintained 
the decreasing trend at 36 months. Specifically, periostin 
was reduced in all OR patients (from 117 to 0 average 
score; average ln[T36/T0], −4.6; DAVE −2.0), whereas in 
the NOR group, it was either stable (NOR3) or increased 
(NOR1 and NOR4), except for NOR2, in whom the 
periostin level decreased. Figure  5 shows the behav-
ior (ln[T36/T0]) of periostin in OR and NOR over time 
(p < 0.05; see also Additional files 1, 4).
Gal-3 was stable at 12 months, but was absent in OR at 
36 months (Gal-3-positive at T0). Gal-3 was not detect-
able at 36 months in NOR (Gal-3-negative at T0) (Addi-
tional file 5).
As reported above, NOR patients, who were char-
acterized as Gal-3-negative at T0 (before treatment), 
presented the same behavior after 36  months of treat-
ment; however, the trend for one patient (NOR2) after 
36 months of treatment was more similar to that of OR 
than NOR patients for each of the main parameters mon-
itored. In fact, in NOR2, both smooth muscle proteins 
and keratins had decreased or were absent at 36 months, 
as was the case for OR patients. Similarly, eosinophils 
and periostin were, respectively, reduced and absent in 
NOR2, as in OR and in contrast to the remaining NOR.
Table 2 summarizes the levels of the main protein classes 
and eosinophils before treatment (T0) and 36 months after 
treatment for each OR and NOR sample. Of note, both the 


























Bronchial reticular basement membrane (RBM) thickness changes  
NOR 
OR 
Fig. 1 Changes in bronchial RBM thickness in omalizumab responders (OR) and non-omalizumab responders (NOR) at baseline and after 12 and 
36 months of anti-IgE treatment
Fig. 2 Evaluation of bronchial eosinophilic infiltration (cells/mm2) in 
omalizumab responders (OR) and non-omalizumab responders (NOR) 
using the natural logarithm of the score fold change, (ln[T36/T0]). 
Negative values indicate a decrease in the eosinophil count at T36; 
positive values indicate an increase in the eosinophil count at T36. 
OR and NOR are classified according to whether they experienced 
a reduction in RBM thickness (OR) or no reduction in RBM thickness 
(NOR) after 12 months of anti-IgE treatment
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file 6) confirm the different trends for OR and NOR in the 
parameters examined at baseline and T36. They also high-
light the different behavior of NOR2 at T36.
Clustering analysis
Protein lists from the 36-month biopsy specimens were 
compared and used to perform an unsupervised clus-
tering analysis. Thus, OR (Gal-3-positive), who were 
correctly segregated at T0 (see Fig. 6a), were again con-
firmed to be part of the same group at 36 months. It is 
noteworthy that patient NOR2 was in this group. In addi-
tion, the remaining three NOR patients (NOR1, NOR3, 
and NOR4, all Gal-3-negative) were segregated in a dif-
ferent cluster (see Fig.  6b), thus confirming them to be 
part of the same NOR group again at 36 months of treat-
ment. These findings confirm the different behavior at 
36 months of patient NOR2, who was segregated with the 
OR group (see Table 2).
Discussion
Biomarkers of severe asthma are currently a major 
research area [14]. Nonetheless, available biomarkers [15] 
are still far from enabling us to select appropriate candi-
dates for biologics [16, 17]. The need for molecular analy-
sis to define phenotypes has been discussed [18], and 
omics sciences have been proposed as a useful approach 
[19].
In this context, current advances in proteomics, mainly 
those based on mass spectrometry, facilitate the discov-
ery-driven studies of new biomarkers in respiratory dis-
eases and improve the clinical reliability of biomarkers 
for asthma [20].
The main focus of the present study was the extension 
of the histological and proteomic analyses to 36 months 
in a group of patients with severe asthma treated with 
omalizumab that we had previously studied at baseline 
and at 12 months [6]. In the previous study, we did not 
have control biopsy specimens from untreated severe 
asthmatic patients and/or healthy persons, since bron-
choscopy and bronchial biopsy are invasive procedures 
that are not readily applicable in these groups.
Although the number of samples was not large for the 
usual statistical analysis, the data obtained illustrate a 
specific trend for both groups of patients (OR and NOR). 
In particular, our results showed that specimens from OR 
patients (Gal-3-positive at baseline) confirm the reduc-
tion in the thickness of bronchial RBM after 36 months 
of treatment with anti-IgE, thus emphasizing the possi-
ble role of omalizumab in reducing airway remodeling 
in some cases of persistent allergic asthma [6]. As for 
molecular components, proteomic analysis showed that 
mainly ECM, keratin, and smooth muscle proteins were 
further reduced at 36  months of therapy in Gal-3-posi-
tive biopsies.
Although Gal-3 was absent in OR at 36  months, this 
does not put OR in the same situation as NOR; in fact, 
OR presented a different proteomic profile, consistent 
Fig. 3 Changes in abundance levels, expressed as the natural loga-
rithm of the score fold change (ln[T36/T0]) for smooth muscle pro-
teins (SMPs) in omalizumab responders (OR) and non-omalizumab 
responders (NOR) at baseline (T0) and after 36 months (T36) of treat-
ment. A negative value indicates a decrease in SMPs at T36; a positive 
value indicates an increase in SMPs at T36. OR and NOR are classified 
according to whether they experienced a reduction in RBM thickness 
(OR) or no reduction in RBM thickness (NOR) after 12 months of anti-
IgE treatment
Fig. 4 Changes in abundance levels, expressed as the natural loga-
rithm of the score fold change (ln[T36/T0]) for keratins in omalizumab 
responders (OR) and non-omalizumab responders (NOR) at baseline 
(T0) and after 36 months (T36). A negative value indicates a decrease 
in keratins at T36; a positive value indicates an increase in keratins at 
T36. In this case, the p value is high; however, if NOR2 is excluded, 
the p value falls to 0.002 (Additional file 1). OR and NOR are classified 
according to whether they experienced a reduction in RBM thickness 
(OR) or no reduction in RBM thickness (NOR) after 12 months of anti-
IgE treatment
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with the reduction in RBM thickness and eosino-
phil counts. In this context, the lack of Gal-3 in OR at 
36 months, combined with the decrease in protein levels 
reported above, may be correlated with an improvement 
in remodelling and inflammatory state.
With respect to periostin, Hanania et al. [21] found that 
patients with high serum periostin had fewer exacerba-
tions after treatment with omalizumab than patients with 
low serum periostin. This predictive role for periostin was 
not confirmed in recent clinical trials [22]. In the present 
study, periostin was not consistently present in the bron-
chial biopsies of either group, and levels decreased fur-
ther only in OR after 36 months of treatment. Therefore, 
based on our data, periostin cannot be regarded as a pre-
dictive biomarker of modulation of airway remodeling.
With regard to the bronchial inflammatory pat-
tern, high eosinophil counts in the bronchi have been 
observed in patients who are eligible for anti-IgE [23] 
and can be considered one of the biomarkers of the Th2 
asthma phenotype. Omalizumab is effective in the treat-
ment of eosinophilic airway inflammation in patients 
with allergic asthma [24]. In the present study, a further 
decrease (compared with 12  months) in eosinophils 
in the biopsy specimens was detected in patients who 
were Gal-3-positive at baseline (OR), whereas eosino-
phil counts increased in Gal-3-negative patients (NOR). 
These findings are consistent with recent data reporting 
increased and decreased Gal-3 levels in eosinophilic and 
neutrophilic asthma, respectively [25]. Gal-3 might also 
predict decreased eosinophilic inflammation in the bron-
chi in patients receiving omalizumab.
Finally, the further decrease in smooth muscle proteins 
(i.e., actins and myosins) after 36 months is interesting and 
thus supports the hypothesis of improved pulmonary func-
tion observed in some omalizumab-treated asthmatics [26].
If this was the case, Gal-3 would be a very useful tool for 
predicting clinical improvement in pulmonary function. 
This observation is of particular clinical interest, since the 
above-mentioned studies showed that, as far as FEV1 is 
Fig. 5 Changes in abundance levels expressed as the natural loga-
rithm of the score fold change (ln[T36/T0]) for periostin in omali-
zumab responders (OR) and non-omalizumab responders (NOR) at 
baseline (T0) and after 36 months (T36) of anti-IgE treatment. A nega-
tive value indicates a decrease in periostin at T36; a positive value 
indicates an increase in periostin at T36. OR and NOR are classified 
according to whether they experienced a reduction in RBM thickness 
(OR) or no reduction in RBM thickness (NOR) after 12 months of anti-
IgE treatment
Table 2 Levels of  eosinophils (cells/mm2) and  abundance (score) for  smooth muscle proteins, periostin, and  keratins 
at baseline (T0) and after 36 months of anti-IgE treatment (T36)
Increased values (or substantially unchanged) at T36 compared to T0 are reported in italic. For more details about available proteins see Additional file 2
OR1 OR2 OR3 OR4 NOR1 NOR2 NOR3 NOR4
Eosinophils
 T0 19 31 58 115 0 10 10 9
 T36 3 9 4 5 11 3 20 27
Smooth muscle proteins
 T0 288 80 198 494 0 0 20 0
 T36 10 20 0 0 168 0 30 98
Periostin
 T0 30 160 130 150 0 30 120 0
 T36 0 0 0 0 20 0 106 20
Keratins
 T0 1990 1902 1630 2047 1404 1910 1892 1676
 T36 574 276 100 266 2106 40 1330 1400
Galectin-3
 T0 10 10 30 20 0 0 0 0
 T36 0 0 0 0 0 0 0 0
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concerned, not all patients improved with omalizumab. In 
responsive patients, omalizumab can be considered a dis-
ease-modifying treatment and Gal-3 a potential biomarker.
Our findings confirm the role of Gal-3 as a biomarker 
of long-term reduction in bronchial RBM, eosinophil 
inflammation, and muscular components in omali-
zumab-treated severe asthmatics. In addition, our data 
support the molecular model, indicating that the pres-
ence of Gal-3 may have a role in the dissociation of the 
IgE–FcεRI complex and enhance the effectiveness of anti-
IgE therapy for remodelling in Gal-3-positive patients 
[7]. Further studies based on larger samples or a cellular 
model are required to confirm the role of Gal-3 in the 
dissociation of the IgE–FcεRI complex.
Bronchial analysis is useful for investigating the origin 
and mechanisms of disease; however, in clinical practice, 
it is necessary to analyze less invasive samples, such as 
urine and blood. We intend to perform such an analysis 
in the context of the PROXIMA study (Patient-Reported 
Outcomes and Xolair® In the Management of Asthma), 
an observational, multicenter, cross-sectional, prospec-
tive cohort study conducted at 25 centers [27]. In fact, 
PROXIMA involves an ancillary study to explore protein 
biomarkers in urine and plasma and to characterize them 
according to severe allergic asthma and treatment effects. 
In this context, the possible correlation between Gal-3 
and evolution of pulmonary function with omalizumab 
will be investigated in greater depth.
Conclusions
We investigated the long-term effects of anti-IgE treat-
ment. In particular, proteomic signatures combined with 
histological data enabled us to confirm the following:
  • In bronchial biopsy samples from severe asthmatics, 
Gal-3 acts as a biomarker of modulation of airway 
remodeling upon treatment with omalizumab.
  • There seems to be a relationship between Gal-3 posi-
tivity and improvement in pulmonary function.
  • In severe asthmatics treated with omalizumab, Gal-3 
is a sufficiently effective biomarker of both short- and 
long-term reduction in the thickening of bronchial 





























































































































Fig. 6 Unsupervised hierarchical clustering of protein lists obtained by analyzing lung biopsies from omalizumab responders (OR, blue) and non-
omalizumab responders (NOR, red). a Before (baseline). b After 36 months of anti-IgE treatment. The clusters obtained were based on SEQUEST 
score value and proved to be well structured (agglomerative coefficients >0.7). OR and NOR are classified according to whether they experienced a 
reduction in RBM thickness (OR) or no reduction in RBM thickness (NOR) after 12 months of anti-IgE treatment
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